{"id":58942,"date":"2023-06-21T13:47:21","date_gmt":"2023-06-21T12:47:21","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&p=58942"},"modified":"2023-06-21T13:47:21","modified_gmt":"2023-06-21T12:47:21","slug":"treatment-algorithm-for-managing-treatment-resistant-depression-charles-nemeroff-apa-2023","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/psychiatric-disorders\/conference-hub\/treatment-algorithm-for-managing-treatment-resistant-depression-charles-nemeroff-apa-2023\/","title":{"rendered":"Treatment algorithm for managing treatment-resistant depression: Charles Nemeroff, APA 2023"},"content":{"rendered":"
Guidance following the failure of monotherapy when treating depression is limited, as such clinicians usually take a trial and error approach to treatment, a treatment algorithm could help personalise patient care and achieve improved outcomes. It was a pleasure to talk with Dr. Charles Nemeroff<\/strong> (The University of Texas at Austin, Dell Medical School, Austin, TX, USA) to discuss the treatment algorithm which navigates the management of treatment-resistant depression, and major depression.<\/p>\n The abstract entitled \u2018Current and Future Treatment of Depression: Glass Half Full or Half Empty?<\/em><\/a>\u2019 was presented at the\u00a0American Psychiatric Association<\/a>, 20-24 May 2023, San Francisco, CA, USA.<\/p>\n Questions<\/b>:<\/p>\n Disclosures<\/b>: Charles Nemeroff discloses consulting for Intracellular Therapies, Sage Therapeutics, ANeuroTech, Silo Pharma, Relmada Therapeutics, Engrail Therapeutics, EmbarkNeuro, GoodCap Pharmaceuticals Inc., Senseye Inc., Pasithea Therapeutics Corp., SynapseBio Inc., BioXCel Therapeutics, Clexio Biosciences Ltd., Ninnion LLLC., Heading Health LLC. and MAPS Public Benefit Corporation; serving on advisory boards for ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Heading Health, Pasithea Therapeutic Corp. and Sage; and having major stock\/ shares in Seattle Genetics, Antares, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, Naki Health and Relmada Therapeutics.<\/p>\n Support<\/b>: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.<\/p>\n\n